Edgar Filing: ENDOCARE INC - Form 8-K

ENDOCARE INC Form 8-K December 13, 2007

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2007

ENDOCARE, INC.

(Exact name of registrant as specified in its charter)

001-15063

Delaware (State or Other Jurisdiction of (Commission Incorporation) File Number)

33-0618093 (I.R.S. Employer **Identification Number**)

201 Technology Drive Irvine, California 92618

(Address of Principal Executive Offices, including zip code)

(949) 450-5400

(Registrant s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Table of Contents 2

TABLE OF CONTENTS

<u>Item 8.01 Other Events.</u> <u>SIGNATURES</u>

Table of Contents 3

Edgar Filing: ENDOCARE INC - Form 8-K

Table of Contents

Item 8.01 Other Events.

Endocare, Inc. (the Company) recently received an aggregate of \$1.125 million in proceeds from the exercise of options held by William J. Nydam, a former officer of the Company. An aggregate of 166,667 shares were issued upon exercise of the options, which had an exercise price of \$6.75 per share.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENDOCARE, INC.

December 13, 2007 By: /s/ Michael R. Rodriguez

Michael R. Rodriguez

Senior Vice President, Finance and

Chief Financial Officer

Table of Contents 4